Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Lee, Young-Sun | - |
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | An, Hyunggin | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.accessioned | 2022-02-11T06:42:00Z | - |
dc.date.available | 2022-02-11T06:42:00Z | - |
dc.date.created | 2022-02-08 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/135307 | - |
dc.description.abstract | Background Despite antiviral therapy, liver function often fails to recover in patients with hepatitis B virus (HBV)-related decompensated cirrhosis. Aim To establish a prognostic model to predict re-compensation in patients starting potent nucleos(t)ide analogue (NUC) therapy Methods We analysed 311 consecutive patients with HBV-related decompensated cirrhosis treated with entecavir or tenofovir. The primary outcome was re-compensation, defined as recovery to a Child-Pugh score of 5. The BC2AID score was developed from a cohort of 152 subjects based on competing risk models and validated in another cohort of 159 subjects. Results Re-compensation occurred in 57.2% and 66.7% of the subjects in the derivation and validation cohorts, respectively. Six independent predictors for re-compensation were identified in the derivation cohort and these comprised the BC2AID score: bilirubin <= 5 mg/dL (adjusted sub-distribution hazard ratio [aSHR] 2.18), absence of severe complications (aSHR 2.78), alpha-fetoprotein (AFP) >= 50 ng/mL (aSHR 2.54), alanine aminotransferase >= 200 IU/L (aSHR 2.62), international normalised ratio <= 1.5 (aSHR 2.37) and <= 6 months from initial decompensation until initiation of NUCs (aSHR 4.79). In the validation cohort, the area under the receiver operating characteristic curve of the BC2AID score for re-compensation within 1 year of NUC therapy was significantly higher than that of the Child-Pugh, MELD, MELDNa and BE3A scores (0.813 vs 0.691, 0.638, 0.645 and 0.624, respectively; all P < 0.05). Conclusions Six clinical parameters, including AFP and the timing of antiviral therapy, were combined into a scoring system to accurately predict early re-compensation in patients with HBV-related decompensated cirrhosis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | ENTECAVIR | - |
dc.title | Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young-Sun | - |
dc.contributor.affiliatedAuthor | Yim, Sun Young | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.identifier.doi | 10.1111/apt.16658 | - |
dc.identifier.scopusid | 2-s2.0-85117187675 | - |
dc.identifier.wosid | 000708129200001 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.55, no.1, pp.83 - 96 | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 55 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 83 | - |
dc.citation.endPage | 96 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ENTECAVIR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.